Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 6/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23780055 | 1.00 | UGCG (0.37) | UGCGTLR9TLR8TLR7MAPT | |
| SCHEMBL23780157 | 0.93 | UGCG (0.43) | UGCGTLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL31109442 | 0.93 | GRIN2B (0.40) | UGCGTLR9TLR8TLR7IDO1 | |
| SCHEMBL31109351 | 0.93 | UGCG (0.39) | UGCGTLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL31109358 | 0.93 | ALDH1A1 (0.36) | UGCGTLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL23780068 | 0.93 | GRIN2B (0.40) | UGCGTLR9TLR8TLR7IDO1 | |
| SCHEMBL23780199 | 0.93 | UGCG (0.39) | UGCGTLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL23780171 | 0.93 | ALDH1A1 (0.36) | UGCGTLR9TLR8TLR7L3MBTL1 | |
| SCHEMBL23780238 | 0.92 | KMT2A (0.38) | UGCGTLR9TLR8TLR7TP53 | |
| SCHEMBL23780062 | 0.91 | HSD17B10 (0.39) | TLR9TLR8TLR7IDO1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873464-B1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-07-30 | — | — | EP | claimed |
| US-12091405-B2 | Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091405-B2 | Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, KYNU | UGCG 2405/4885TLR9 2707/4885TLR8 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.